In contrast, when patients with FLT3-ITD-mutated AML relapsing after allogeneic stem-cell transplantation received sorafenib, the outcome may differ profoundly, as suggested by long-term remissions in selected patients (19, 20). Here, FLT3 is linked to acute myeloid leukemia.